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Abstract
Background: The number of people living with HIV (PLHIV) is increasing in the UK. This study estimated the annual
population cost of providing HIV services in the UK, 1997–2006 and projected them 2007–2013.
Methods: Annual cost of HIV treatment for PLHIV by stage of HIV infection and type of ART was calculated (UK pounds,
2006 prices). Population costs were derived by multiplying the number of PLHIV by their annual cost for 1997–2006 and
projected 2007–2013.
Results: Average annual treatment costs across all stages of HIV infection ranged from £17,034 in 1997 to £18,087 in 2006
for PLHIV on mono-therapy and from £27,649 in 1997 to £32,322 in 2006 for those on quadruple-or-more ART. The number
of PLHIV using NHS services rose from 16,075 to 52,083 in 2006 and was projected to increase to 78,370 by 2013. Annual
population cost rose from £104 million in 1997 to £483 million in 2006, with a projected annual cost between £721 and £758
million by 2013. When including community care costs, costs increased from £164 million in 1997, to £683 million in 2006
and between £1,019 and £1,065 million in 2013.
Conclusions: Increased number of PLHIV using NHS services resulted in rising UK population costs. Population costs are
expected to continue to increase, partly due to PLHIV’s longer survival on ART and the relative lack of success of HIV
preventing programs. Where possible, the cost of HIV treatment and care needs to be reduced without reducing the quality
of services, and prevention programs need to become more effective. While high income countries are struggling to meet
these increasing costs, middle- and lower-income countries with larger epidemics are likely to find it even more difficult to
meet these increasing demands, given that they have fewer resources.
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Introduction
The UK has the fastest growing HIV epidemic in Western
Europe [1]. The number of PLHIV alive and using NHS services
have increased, partly due to more effective ART regimens
resulting in their longer survival [2], partly due to uninfected
people continuing to be infected with HIV either in the UK or
abroad [3]. This combination has resulted in increasing number of
PLHIV using NHS services [4] which is likely to have resulted in
increased population costs for HIV treatment and care. The aim
of this study was to estimate the treatment and care costs for
PLHIV in the UK population by stage of HIV infection and type
of ART between 1997 and 2006 and project costs for 2007–2013.
Methods
The National Prospective Monitoring System on the use, cost
and outcome of HIV service provision in UK hospitals - HIV
Health-economics Collaboration (NPMS-HHC) monitors pro-
spectively the effectiveness, efficiency, equity and acceptability of
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treatment and care in participating HIV units since 1996. Using
an agreed minimum dataset, standardized data are routinely
collected in clinics and transferred to the NPMS-HHC Coordi-
nating and Analytic Centre, ensuring both patient and clinic
confidentiality. The data analyses are performed both at clinic and
aggregate levels. The clinic specific analyses remain confidential,
while aggregate analyses become public documents [5,6].
Use and Cost of Hospital Services
Information on the use of hospital inpatient (IP), outpatient
(OP), and dayward (DW) services between 1st January 1997 and
31st December 2006, was obtained from 14 hospitals participating
in this analysis. The mean number of IP days, OP and DW visits
per patient-year (PPY) by stage of HIV infection - asymptomatic,
symptomatic non-AIDS or AIDS - were calculated per patient-
year from 1997 to 2006. The methods used for calculating the
mean use of hospital services per patient year (PPY) were similar to
those employed in our previous studies [2,7,8].
The denominator consisted of the total duration of follow up for
all patients during a calendar year, from when they were first seen
during that year till the end of the year if still alive, or when they
died, or if they were lost to follow up, which ever came first.
Numerators were calculated by summing the use of IP, OP or DW
services and annual mean use of services PPY were calculated
using the following formula:
M~
Pn
i~1
Pk
j~1
Sij
Pn
i~1
Pk
j~1
(tij{ti(j{1))
|365
Where: n = total number of individuals;
k = day of censoring;
Sij = use of service of individual i at jth day;
tij = number of days since diagnosis of stage of HIV infec-
tion of individual i and remaining within the same
stage;
M = mean of services S per patient-year by stage of HIV
infection.
Annual cost PPY estimates for HIV-service provision for
individual PLHIV by stage of infection were produced by linking
mean number of IP days, OP visits and DW visits with their
respective unit costs (2006 prices). The unit cost estimates for an
average IP day was £475, average OP visit was £94 and £384 for a
DW visit [9]. Costs were in UK pounds at 2006 prices.
Unit Costs of Antiretroviral Therapy
Average costs for treatment regimens were based on London
Specialised Commissioning Group prices of each licensed
antiretroviral (ARV) drug. Average annual cost, including 17.5%
value added tax (VAT), were calculated for different antiretroviral
therapy (ART) regimens - mono-, dual-, triple- or quadruple-or-
more therapy - and stratified by stages of HIV infection:
asymptomatic, symptomatic non-AIDS or AIDS.
Overall Cost of Services by Stage of HIV Infection and
Type of Antiretroviral Therapy
The costs for different ART by stage of HIV infection were
added to the cost for IP, OP and DW services for each of the
clinical stages; costs of ‘other’ drugs and tests and procedures
performed [9], were added to obtain the total direct costs for
treatment and care for PLHIV by stage of HIV infection and type
of ART. The primary analysis was from a public service
perspective focused on hospital costs [10], while annual population
cost-estimates were also presented including community care costs
[9] as indicated.
PLHIV Using NHS Services by Type of Antiretroviral
Therapy
The annual number of PLHIV by stage of HIV infection using
NHS services by type of ART prescribed, were obtained from the
Health Protection Agency (HPA). Not all of these data sets were
complete; for some PLHIV their stage of HIV infection was known
but the type of ART prescribed was unknown. These individuals
were proportionally distributed across the respective ART strata,
ensuring that the proportion of subjects represented in each
category remained unchanged. Secondly, HPA figures indicated
that no subjects had been prescribed quadruple-or-more therapy in
1997 and 1998, which was unlikely and probably due to incorrect
reporting during those calendar years. For these years linear least
squares regression analysis [11] was used to estimate the number of
PLHIV likely to have been prescribed quadruple- or-more therapy.
UK HIV Population Cost Estimate
To obtain the population cost estimates, the total annual
treatment and care costs for a PLHIV by stage of HIV infection
and type of ART were multiplied by the number of PLHIV within
those categories for each year. Costs were then added across stages
of HIV and types of ART regimens to obtain a total population
cost by year, while community care costs were also included for
population estimates [9].
UK HIV Population and Cost Projection
Projections were made to estimate future costs for the years 2007
to 2013 and these were investigated using both the linear and higher
order polynomial least squares regression analyses [11]. Using
proportion of variance explained as a measure of goodness of fit of
the models, the linear least squares analyses produced the best fit and
was therefore presented in this paper. The projections were based on
the trends observed over 1997–2006 and three scenarios were
investigated: the first scenario extrapolated total annual population
costs 1997–2006 to 2007–2013. The second scenario extrapolated the
total number of PLHIV who used HIV services between 1997 and
2006 to 2007 and 2013. The average annual cost of treating a
PLHIV across all stages of HIV infection in 2006 was calculated and
this was multiplied by the projected numbers of PLHIV using NHS
services for the years 2007–2013. The third scenario extrapolated
PLHIV for each of the three stages of HIV infection from 1997–
2006 to 2007–2013. Average 2006 annual cost of treatment and care
for stage of HIV infection was used to extrapolate cost 2007–2013 by
stage of HIV infection. Total projected annual treatment costs were
obtained by adding annual population costs of each of the three
stages of HIV infection across all three stages.
Results
26,033 PLHIV were managed in 14 UK HIV centres between
1997 and 2006. Seventy six percent of the study sample were men
and 51% of all PLHIV were Caucasian. Of those whose sexual
orientation was known, 62% were men who have sex with men
(MSM), while 4.5% were known to be or have been injecting drug
users (IDUs). Seventy nine percent of the HIV subjects had
attended HIV centres in London for HIV care, while 15% were
known to have attended more than one HIV centre within the UK
during the study period.
Rising Population HIV Treatment Costs UK 1997-2013
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Use of Hospital Services, 1997–2010
Annual Mean Number of Inpatient Days. Average mean
number of IP days during the study period was 2.1 PPY for
asymptomatic patients, which did not change substantially over
time. Average mean number of IP days for symptomatic non-AIDS
patients increased from 1.8 in 1997 to 2.7 PPY in 2006, while the
average number of IP days for AIDS patients decreased from 7.7 in
1997 to 6.7 PPY in 2002 but increased to 10.9 in 2006 (Figure 1).
Annual Mean Number of Outpatient Visits. Average
mean number of OP visits for asymptomatic patients was 6.5 PPY
which did not change substantially over time, nor did the average
mean number of OP visits for symptomatic non-AIDS patients at
around 8.3 PPY. For AIDS patients, the mean number of OP visits
decreased from 11.8 in 1997 to 7.0 PPY in 2006 (Figure 2).
Annual Mean Number of Dayward Visits. The average
mean number of DW visits for asymptomatic patients increased
from 0.3 in 1997 to 1.3 PPY in 2006. The average mean number
of DW visits for symptomatic non-AIDS patients remained
constant at 0.7 PPY, while for AIDS patients the average mean
DW visits increased from 1.5 in 1997 to 2.0 PPY in 2006, having
first decreased to 0.6 in 2000 (Figure 3).
Annual Cost of Treatment and Care Services by Type of
ART
Treatment and care costs for PLHIV at different stage of HIV
infectionanddifferent treatment regimens increasedover time (Table1).
Mono-therapy. For asymptomatic individuals in 1997 the
annual cost of care was £8,308, which increased to £10,020 in 2006.
For those with symptomatic non-AIDS, the 1997 cost of £12,076
decreased to £11,487, while for AIDS patients on mono-therapy, the
annual costs increased from £30,717 in 1997 to £32,760 by 2006.
Dual-therapy. For asymptomatic PLHIV on dual therapy, the
1997 cost of £11,376 increased to £13,351. For patients with
symptomatic non-AIDS, the annual cost increased from £14,685 in
1997 to £15,692 in 2006, while for AIDS patients on dual therapy, this
increased from £33,726 in 1997 to £36,580 per patient-years in 2006.
Triple-Therapy. For asymptomatic PLHIV on triple therapy,
annual costs increased from £16,347 to £18,280 in 2006. For
patients with symptomatic non-AIDS annual costs increased from
£19,806 to £21,597 in 2006, while for AIDS patients annual costs
varied from £38,887 in 1997 to £41,747 in 2006.
Quadruple-or-more-Therapy. Annual cost for those asymp-
tomatic PLHIV on quadruple-or-more therapy ranged from
£18,839 in 1997 to £23,775 in 2006. Similarly annual costs
increased from £22,724 to £25,135 for PLHIV with symptomatic
non-AIDS, while for AIDS patients annual costs increased from
£41,383 to £48,055 in 2006.
It was of interest to note that the proportion spent on ART did
not change significantly over time for any of three stages of HIV
infection nor for the four ART treatment categories (Table 1).
Population Cost Treatment and Care 1997–2006 and
2007–2013
People Living With HIV Using NHS Services. The total
number of PLHIV who used NHS services for treatment and care
increased from 16,075 patients in 1997 to 52,083 by 2006, an
increase that was seen across all stages of HIV infections.
However, the proportion of asymptomatic PLHIV increased
from 38% to 49% between 1997 and 2006, with the proportion of
symptomatic non-AIDS patients and AIDS patients both
decreasing, from 34% to 28% and from 28% to 23%
respectively between 1997 and 2006 (Table 2).
Annual Population Costs 1997–2006. The population costs
increased from £104 million in 1997 to £483 million in 2006
(Figure 4). If an estimate for community care costs was included,
population costs rose from £164 million in 1997 to £683 million in
2006 (Figure 5).
In 1997 the total population cost for treating asymptomatic
PLHIV was estimated at £22 million which increased to £162
million in 2006, while proportionally their annual cost increased
from 21% in 1997 to 33% in 2006. Annual treatment costs for
patients with symptomatic non-AIDS also increased, from £39
million to £146 million, but less dramatically compared with
asymptomatic PLHIV; proportionally this group generated 37% of
population costs in 1997, which decreased to 30% in 2006. For
AIDS patients, annual population costs increased from £43 million
to £176 million in 2006, but proportionally costs generated by this
group decreased from 42% in 1997 to 36% by 2006.
Projected Annual Population Costs 2007–2013. The first
scenario, which projected the annual population costs from 1997–
2006 estimated that by 2013 the annual direct population cost
would increase to £758 million or £1,065 million if community
care costs were included (Figures 4 and 5).
The second scenario was based on the projected increase in total
number of PLHIV by 2013. Multiplying the estimated number of
PLHIV using NHS services by 2013 by the average 2006 per
Figure 1. Mean Inpatient Days per Patient-year by Stage of HIV Infection and Year.
doi:10.1371/journal.pone.0015677.g001
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patient-year costs, the annual population cost was estimated to
increase to £727 million by 2013, or £1,027 million when
including community care costs (Figures 4 and 5).
For the third scenario, the number of PLHIV by stage of HIV
infection were projected and multiplied by the average annual
2006 cost for each stage and a total annual population cost of £721
million was estimated by 2013, or £1,019 million including
community care (Figures 4 and 5).
Discussion
This study estimated that the direct population cost for
treatment and care of PLHIV in the UK has risen 4.6 fold
between 1997 and 2006, from £104 million to £483 million
respectively. The number of PLHIV using NHS services during
this period tripled from 16,075 to 52,083 PLHIV: the greatest
increase was seen among asymptomatic PLHIV and less so among
PLHIV with symptomatic non-AIDS or AIDS.
There has been an increase in mean annual IP days and DW
visits among AIDS patients, while number of OP visits declined.
Increased use of IP services was also observed among PLHIV with
symptomatic non-AIDS while asymptomatic PLHIV used more
DW services over time. These increases in annual cost of
treatment and care over time were most pronounced for AIDS
patients on quadruple-or-more ART. This may be due to these
ART-experienced patients having to use more IP and DW
services, as well as their increased use of new and more expensive
ARVs in the second half of the study period.
The majority of patients were seen in London clinics and this
may have skewed our findings, though overall costs did not seem
to differ substantially between London and out-of-London sites
during the study period [9]. This analysis is furthermore
contingent on the fact that most if not all PLHIV using NHS
services during the study, were diagnosed and reported to the
HPA. Examples were described in the methods section of how
some of the HPA data had to be adjusted because of missing data.
When the annual population costs were projected using three
different methods, the estimated population costs increased to
between £721 million and £758 million by 2013, a 1.5 fold
increase from the 2006 baseline. The three scenarios produced
similar estimates, with only a 5% difference between the lowest
and highest estimates. The accuracy of these estimated projected
figures of PLHIV using NHS services were compared with more
recently figures published by HPA [12]. The recent HPA figures
Figure 2. Mean Outpatient Visits Per Patient-year by Stage of HIV Infection and Year.
doi:10.1371/journal.pone.0015677.g002
Figure 3. Mean Dayward Visits Per Patient-year by Stage of HIV Infection and Year.
doi:10.1371/journal.pone.0015677.g003
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were 56,377, 57,930 and 62,018 for 2007, 2008 and 2009
respectively; the estimated figures were 53,842, 57,930 and 62,018
for respective years, an underestimate of 5% for each year.
Another potential source of error for estimating the population
cost was the extent that HIV- services also used generic, non-HIV
services to operate. While the unit costs include facility-level
overheads, other general costs covered by the NHS, such as its
drug procurement system, general staff training and other more
general non-HIV indirect support, may not have been included in
these estimates. However, these points suggest that the estimates
produced in this study are likely to underestimate the true
population cost of delivering HIV services in the NHS.
At the end of 2008 the number of people living with HIV in
the UK was estimated to be 83,000, of whom an estimated 27%
were unaware of being infected [3]; 7,298 people were newly
diagnosed with HIV in 2008, or 9% of the estimated 83,000
PLHIV in the UK and 12% of the 61,213 PLHIV reportedly
using NHS services during 2008. A recent study in the UK,
confirmed the benefit for starting ART early with CD4 count
,350 cells/mm3 [13]. The annual cost of treatment and care, for
those who started ART with a CD4 count .200 cells/mm3, is
30–35% less than for those who start ART with a CD4 count #
200 cells/mm3. However, between 1996 and 2006, of 5,541
PLHIV who started first-line therapy, 55% were diagnosed with a
CD4 count # 200 cells/mm3, many of whom were Black
Africans [13]. It is likely that many of the PLHIV, who are
currently unaware of being infected, may well present late in their
disease course with a CD4 count # 200 mm3. Starting more
PLHIVs with a CD4 count ,350 cells/mm3 will increase the
number of people receiving HAART, which will initially add to
Table 1. Annual cost of treatment and care by Stage of HIV Infection and different types of Anti-Retroviral Therapy in UK pound,
2006 UK prices and proportion of cost due to Antiretroviral Therapy (%).
Year Monotherapy Dual therapy Triple therapy Quadruple or more therapy
Asymp-
tomatic
Symptomatic
Non AIDS AIDS
Asymp-
tomatic
Symptomatic
Non AIDS AIDS
Asymp-
tomatic
Symptomatic
Non AIDS AIDS
Asymp-
tomatic
Symptomatic
Non AIDS AIDS
1997 £8,308 £12,076 £30,717 £11,376 £14,685 £33,726 £16,347 £19,806 £38,887 £18,839 £22,724 £41,383
(46%) (36%) (13%) (61%) (47%) (21%) (73%) (61%) (31%) (76%) (66%) (35%)
1998 £8,642 £13,008 £29,609 £11,660 £15,907 £32,467 £16,542 £21,006 £37,626 £19,528 £23,970 £40,621
(48%) (34%) (15%) (62%) (46%) (22%) (73%) (59%) (33%) (77%) (64%) (38%)
1999 £8,552 £13,481 £30,431 £11,619 £16,553 £33,542 £16,506 £21,980 £38,483 £19,894 £25,140 £42,005
(50%) (29%) (14%) (63%) (43%) (22%) (74%) (57%) (32%) (78%) (62%) (38%)
2000 £8,083 £11,299 £29,274 £10,981 £14,352 £32,423 £15,941 £19,683 £37,242 £18,734 £22,476 £40,380
(51%) (33%) (14%) (64%) (47%) (22%) (75%) (62%) (32%) (79%) (66%) (38%)
2001 £7,859 £11,489 £32,229 £10,906 £14,310 £35,493 £15,827 £19,521 £39,981 £20,613 £23,709 £44,911
(52%) (35%) (13%) (65%) (47%) (21%) (76%) (62%) (30%) (82%) (68%) (37%)
2002 £8,145 £11,901 £29,059 £11,358 £14,314 £32,164 £16,257 £19,954 £36,978 £21,449 £26,414 £42,235
(49%) (35%) (14%) (64%) (46%) (22%) (75%) (61%) (32%) (81%) (71%) (41%)
2003 £8,176 £13,435 £32,227 £11,319 £15,611 £35,454 £16,422 £21,474 £40,221 £21,747 £26,089 £45,831
(49%) (34%) (13%) (64%) (43%) (21%) (75%) (59%) (30%) (81%) (66%) (39%)
2004 £8,774 £12,272 £28,988 £11,777 £15,483 £32,206 £17,254 £21,621 £37,311 £22,827 £26,659 £43,436
(48%) (28%) (15%) (61%) (43%) (23%) (74%) (59%) (34%) (80%) (67%) (43%)
2005 £8,685 £12,192 £30,566 £11,864 £17,048 £33,864 £16,930 £22,713 £39,045 £22,979 £28,603 £45,661
(50%) (17%) (14%) (64%) (41%) (22%) (74%) (56%) (32%) (81%) (65%) (42%)
2006 £10,020 £11,482 £32,760 £13,351 £15,692 £36,580 £18,280 £21,597 £41,747 £23,775 £25,135 £48,055
(43%) (23%) (11%) (58%) (43%) (20%) (69%) (59%) (30%) (76%) (72%) (39%)
doi:10.1371/journal.pone.0015677.t001
Table 2. Number of People Living with HIV Using NHS
Services by Stage of HIV 1997–2006 [4] and Projected Figures
for 2007–2013 (in italics).
Year HIV Population (%)
Asymptomatic
Symptomatic
non-AIDS AIDS Total
1997 6,124 (38%) 5,384 (34%) 4,567 (28%) 16,075
1998 5,835 (32%) 6,975 (38%) 5,525 (30%) 18,335
1999 6,833 (33%) 7,994 (37%) 6,288 (30%) 21,114
2000 8,055 (35%) 8,347 (37%) 6,338 (28%) 22,740
2001 10,015 (38%) 9,088 (34%) 7,253 (28%) 26,356
2002 12,787 (40%) 10,635 (34%) 8,115 (26%) 31,537
2003 15,932 (43%) 11,544 (32%) 9,203 (25%) 36,679
2004 18,794 (45%) 12,834 (31%) 10,009 (24%) 41,637
2005 21,656 (46%) 14,590 (31%) 10,779 (23%) 47,025
2006 25,385 (49%) 14,750 (28%) 11,947 (23%) 52,083
2007 25,485 (47%) 15,979 (30%) 12,378 (23%) 53,842
2008 27,729 (48%) 17,027 (29%) 13,173 (23%) 57,930
2009 29,974 (48%) 18,075 (29%) 13,969 (23%) 62,018
2010 32,218 (49%) 19,123 (29%) 14,764 (22%) 66,106
2011 34,462 (49%) 20,171 (29%) 15,560 (22%) 70,194
2012 36,707 (49%) 21,219 (29%) 16,355 (22%) 74,282
2013 38,951 (50%) 22,267 (28%) 17,151 (22%) 78,370
doi:10.1371/journal.pone.0015677.t002
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the financial burden of the NHS. However, starting PLHIV on
cost-effective regimens earlier, will maintain them in better
health, resulting in the use of fewer health or social services and
thereby generating fewer treatment and care costs, while enabling
them to remain socially and economically active members of
society.
Increasing population costs for HIV treatment and care are
raising serious concerns in high-income countries, especially as
many are going through periods of cutting public expenditure [14]
as a consequence of the global economic downturn. This issue is
even more pertinent for middle- and lower-income countries. As
part of universal access, many of these countries have been
increasing treatment and care services and the number of PLHIV
currently on ART has reached 5 million PLHIV [15]. While this
constitutes a great success, if countries want to continue to increase
their ART coverage the issue of providing sustainable quality
Figure 4. Annual Average UK Direct Population Cost 1997–2006 and Projections 2007–2013 based on three Scenarios (UK 2006
prices).
doi:10.1371/journal.pone.0015677.g004
Figure 5. Annual Average UK Population Cost 1997–2006 and Projections 2007–2013 based on three Scenarios all including
Community Care Costs (UK 2006 prices).
doi:10.1371/journal.pone.0015677.g005
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services in the context of limited country resources raises serious
questions. Lessons from high-income countries teach us that
increased coverage is going to result in increased population costs.
Will these countries be able to provide ART free-at-point of
delivery on a life-long basis, as is the underlying assumption in
high-income countries [16]? The recent change in WHO criteria
to start ART when CD4 count ,350 cells/mm3 [17] increases the
number of PLHIV in need of starting on ART, and also raises the
ethical issue whether PLHIV with more severe HIV disease should
receive ART first, or should PLHIV with higher CD4 counts have
preference because their treatment and care costs are less than
those with higher CD4 counts? Starting ART early is effective [18]
and cost-effective [8,19] in resource limited settings and if ART is
focused on these PLHIV, one could argue that there will be more
resources available that will enable more PLHIV to be receiving
ART, while allowing them to remain socially and economically
active. These are some of the issues, which countries and resource-
limited ones in particular, will have to face. Furthermore, many
low-income countries will need to make these choices with the
knowledge that many of them, at least for the foreseeable future,
will continue to be reliant on donor agencies or countries to sustain
their treatment and care services [20].
Trying to curtail the costs of service provision is one measure
by which one could try and curtail the population cost. Measures
which are being used range from sending laboratory test results
by email, home delivery of the drugs to the patient, which is
exempted from VAT in the UK, to using the most cost-effective
regimens [13]. Even if the costs could be brought down, without
reducing the quality of services provided, the fact that the
number of new people being infected with HIV continue to
outpace those being put on ART, will continue to drive up
population cost for HIV services.
Only greater prevention efforts will reduce the number of
people becoming infected with HIV. A recent study from the US
suggests that even if incidence is reduced drastically, the number of
people newly infected with HIV will continue to increase [21].
While putting PLHIV on ART will reduce their infectivity and
contribute to reducing the incidence of people newly infected with
HIV [22], this in itself will not be sufficient to reduce incidence in
a large number of settings. Only comprehensive prevention
strategies, responding directly to the epidemic dynamics operating
in each country, will be able to reduce HIV incidence [23]. It is
now recognized that in most instances a combination of
prevention interventions are going to be required to achieve
significant reductions in HIV-incidence [24]. While recent
biomedical interventions - like male-circumcision [25], the
development of a vaccine [26], microbicides [27] and pre-
exposure chemoprophylaxis [28] – constitute important advances,
they are going to be most successful when juxtaposed with relevant
behavioral and structural changes [24]. One of the findings of the
Second Independent Evaluation of the UN Joint Programme on
HIV/AIDS highlighted the relative lack of success of global
prevention programmes, including in high-income countries, and
recommended a greater emphasis on making prevention more
effective and efficient [29]. Policy makers and other relevant
stakeholders need to use evidence-informed HIV prevention,
treatment and care strategies to ensure that PLHIV have full
access to the treatments that they need based on their clinical
condition, which will prolong life, reduce morbidity, reduce
transmission and ultimately deliver the best for both the individual
and public health agendas.
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